BioPharmSignal logoBioPharmSignal

Biotech News

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Innoviva (INVA)Innoviva2026-06-25 13:46 ESTFDA / regulatory

Agreement expands access to XACDURO ® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals) The rate of carbapenem resistant

Open original release

Related news

INVAInnoviva2026-06-25 13:46 EST

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

INVAInnoviva2026-06-25 13:46 EST

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-25 13:46 EST

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

INVAInnoviva2026-06-25 13:46 EST

Innoviva to Participate in Upcoming Investor Conferences

INVAInnoviva2026-06-25 13:46 EST

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

INVAInnoviva2026-06-25 13:46 EST

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

INVAInnoviva2026-06-25 13:46 EST

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-25 13:46 EST

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

INVAInnoviva2026-06-25 13:46 EST

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

INVAInnoviva2026-06-25 13:46 EST

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

View all latest news

Innoviva

Innoviva is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

INVAZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

INVAZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

INVABMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

INVAGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

INVAMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
22.21 USD
Market cap
1.64B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States